Compare Amgen, Inc. (AMGN) vs Fox Corp Class A (FOXA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Fox Corp Class A — how do they compare? Amgen, Inc. trades at $415.73 (market cap $224.14B), while Fox Corp Class A trades at $62.1 (market cap $24.58B). The key difference: Amgen, Inc. is far larger — about 9.1× Fox Corp Class A's market cap, and Amgen, Inc. pays the higher dividend (2.43%). Which is the better fit depends on your goals.
| AMGN | FOXA | |
|---|---|---|
Market Cap | $224.14B | $24.58B |
Sector | Health | Media |
52-Week High | $417.20 | $76.11 |
52-Week Low | $271.18 | $48.79 |
Enterprise Value | $267.45B | $27.94B |
Dividend Yield | 2.43% | 0.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.
Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.
FOXA stock trades at $61.69, down 2.74% today, amid a bullish technical setup with strong support at $60. The company reported robust Q4 2026 results, beating earnings estimates with $1.79 EPS versus $1.44 expected, driven by World Cup advertising and Tubi streaming growth. Revenue rose 28% year-over-year to $4.21 billion in the quarter. Analyst sentiment is evenly split between Buy and Hold ratings, with a consensus price target of $65.33.
The outlook remains positive given strong ad demand and digital momentum, but risks include higher sports costs and reliance on major events. Earnings growth and streaming execution are key catalysts for further upside, though valuation multiples appear reasonable with a P/E of 16.18.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →
